Rocket is bringing lenti back

Also doing well at at Ash was Rocket Pharmaceuticals, which had data on its three lentiviral contenders. This company gets more attention for its AAV-based Danon disease project, but “we think we’re in a position to bring lenti back”, its chief executive, Gaurav Shah, told Evaluate Vantage at the conference.